anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Boundless Bio · pitchdeck

Boundless Bio | IPO Presentation Deck | 51 slides

51 pages · 5 arc beats · 3 loops

Pitchdeck Download JSON
Unlock

Boundless Bio | IPO Presentation Deck | 51 slides

Boundless Bio · 2024-03
arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

5
coverage by narrative range · generated from this deck JSON
Narrative range 22 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem (Identify pain) 5 slides 100% 5/5 slides 100% 5/5 slides · 22 hits
— 0/5 slides
20% 1/5 slides 40% 2/5 slides 100% 5/5 slides
— 0/5 slides
Agitate (Make it worse) 4 slides 100% 4/4 slides 100% 4/4 slides · 19 hits
— 0/4 slides
25% 1/4 slides 75% 3/4 slides 100% 4/4 slides 100% 4/4 slides Solution (Provide relief) 8 slides 100% 8/8 slides 100% 8/8 slides · 35 hits
— 0/8 slides
— 0/8 slides
75% 6/8 slides 100% 8/8 slides
— 0/8 slides
Market Size 3 slides 100% 3/3 slides 100% 3/3 slides · 15 hits
— 0/3 slides
100% 3/3 slides 33.3% 1/3 slides 100% 3/3 slides 66.7% 2/3 slides Why Now 2 slides 100% 2/2 slides 100% 2/2 slides · 9 hits
— 0/2 slides
100% 2/2 slides 50% 1/2 slides 100% 2/2 slides 100% 2/2 slides

Slide inventory

51
every slide · same image gating as the playbook
01
Slide 1
Includes company logo, tagline, and date.front_matter
Open slide detail
02
other
Open slide detail
03
other
Open slide detail
04
Includes a 'Fierce Biotech Fierce 15' award badge.summarize
Open slide detail
05
The slide uses a visual comparison framework to contrast current standard-of-care targets (mutations/fusions) with the company's focus (ecDNA).frame_problem
Open slide detailBeat · Problem (Identify pain)
06
The slide uses a horizontal bar chart format to represent a drug development pipeline.plan_implementation
Open slide detailBeat · Problem (Identify pain)
07
The slide uses a grid layout to present six key executives, each with their name, title, and a list of logos representing their past professional experience.other
Open slide detailBeat · Problem (Identify pain)
08
The slide uses a grid layout for headshots and a vertical column for investor logos.other
Open slide detailBeat · Problem (Identify pain)
09
transition
Open slide detailBeat · Problem (Identify pain)
10
The slide uses Kaplan-Meier survival curves to illustrate the clinical problem.frame_problem
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
11
The slide uses a visual 'X' to indicate the lack of efficacy for amplifications across multiple drug classes.frame_problem
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
12
The slide uses a color-coded matrix to illustrate clinical failure or limited efficacy in amplified tumors.frame_problem
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
13
The slide uses a horizontal timeline to map scientific discovery (Nature/Science papers) against corporate milestones (funding, clinical trials).show_traction
Open slide detailBeat · Agitate (Make it worse)Loop · Cost Of Inaction
14
transition
Open slide detail
15
The slide uses a combination of microscopy images, a circular genomic plot (circos plot), and a diagram of cell division to illustrate the mechanism.frame_problem
Open slide detail
16
Data source: Kim, Nguyen, Turner, et al. 2020 Nature Genetics. Analysis of WGS data from >3,000 tumor and matched normal samples.show_traction
Open slide detail
17
The slide uses a stacked bar chart to show amplification types and a Kaplan-Meier survival curve to show patient outcomes.frame_problem
Open slide detail
18
The slide uses a before-and-after experimental setup with microscopy images and longitudinal data plots to illustrate therapeutic resistance.frame_problem
Open slide detail
19
The slide uses two distinct experimental examples (sequential vs combination inhibition) to illustrate the mechanism of resistance via ecDNA.frame_problem
Open slide detail
20
Uses a 'Whac-a-Mole' analogy to illustrate the limitations of current targeted therapies versus the company's proposed solution.compare_peers
Open slide detail
21
transition
Open slide detailBeat · Solution (Provide relief)
22
The slide uses a telescope metaphor to represent the 'Spyglass' platform, focusing on ecDNA biology.present_solution
Open slide detailBeat · Solution (Provide relief)
23
The slide uses a circular process diagram to map drug candidates to biological mechanisms.present_solution
Open slide detailBeat · Solution (Provide relief)
24
The slide uses a hub-and-spoke diagram to show how the ECHO algorithm integrates into existing clinical NGS workflows to identify patients with ecDNA-driven canpresent_solution
Open slide detailBeat · Solution (Provide relief)
25
transition
Open slide detailBeat · Solution (Provide relief)
26
The slide uses a comparative visual framework to contrast normal vs. stressed replication mechanisms.frame_problem
Open slide detailBeat · Solution (Provide relief)
27
The slide uses a combination of a CRISPR screen scatter plot and a biological process diagram to illustrate the mechanism.present_solution
Open slide detailBeat · Solution (Provide relief)
28
Uses a puzzle piece metaphor to represent the components of a successful therapeutic strategy.present_solution
Open slide detailBeat · Solution (Provide relief)
29
Includes kinase selectivity tree and four tumor volume growth inhibition charts.show_traction
Open slide detail
30
Includes a mechanism of action diagram illustrating 'Therapy Enhanced Synthetic Lethality'.present_solution
Open slide detail
31
Shows synergistic effect of BBI-355 with Palbociclib and Erlotinib.show_traction
Open slide detail
32
The slide uses a process flow diagram to illustrate the progression from single-agent to combination therapy trials.plan_implementation
Open slide detail
33
The slide highlights the 60mg dose as the MTD (Maximum Tolerated Dose) and shows it crosses the threshold for tumor regression.analyze_data
Open slide detail
34
The table uses a grid layout to show AE frequency across different dosage cohorts (20mg, 40mg, 60mg, 80mg Q2D, 80mg 2ON/5OFF, 120mg 2ON/5OFF).analyze_data
Open slide detail
35
Includes legend for dose cohorts and patient IDs; visual evidence of biomarker induction via IHC staining.show_traction
Open slide detail
36
The slide uses a Gantt-style timeline to map trial phases against calendar years.plan_implementation
Open slide detail
37
transition
Open slide detail
38
The slide uses a table structure to map initial drivers to resistance mechanisms, supported by clinical citations and microscopy images.frame_problem
Open slide detail
39
The slide uses a biological mechanism diagram to explain the therapeutic rationale for BBI-825.present_solution
Open slide detail
40
The slide uses a process flow (left to right) to demonstrate the mechanism of action and efficacy.show_traction
Open slide detail
41
Includes two distinct experimental setups: prevention of resistance (left) and treatment of established resistance (right).show_traction
Open slide detail
42
Includes FISH images, bar chart of copy number, Western blot, and a cell growth curve.present_solution
Open slide detail
43
The slide uses a 'STARMAP' acronym to describe the study design.plan_implementation
Open slide detail
44
The slide uses a diagram to link specific cancer types and mutations to resistance mechanisms, ultimately pointing to BBI-825 as the solution.size_opportunity
Open slide detailBeat · Market Size
45
front_matter
Open slide detailBeat · Market SizeLoop · Golden Circle
46
The slide uses two pie charts to represent patient populations and a central circular diagram to illustrate the biological nodes (Replication Stress, Assembly &size_opportunity
Open slide detailBeat · Market SizeLoop · Golden Circle
47
summarize
Open slide detailLoop · Golden Circle
48
The slide uses a timeline-style progression to frame the company's technology as the next logical evolution in cancer treatment.argue_timing
Open slide detailBeat · Why NowLoop · Why Now
49
front_matter
Open slide detailBeat · Why NowLoop · Why Now
50
The chart at the bottom illustrates the 'ecDNA revolution' alongside 'Molecular biology' and 'NGS' revolutions.cite_precedent
Open slide detail
51
The table uses a clear contrast-based layout to differentiate the two lead molecules.compare_peers
Open slide detail